Marketing-authorisation holder · United States
Genentech, Inc.
59 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
59 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 59
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Actemra162mg/0.9ml · Injection | Tocilizumab | United States | Marketed | 2018 |
| ACTEMRA200mg/10ml | 400mg/20ml | 80mg/4ml · Injectable | Tocilizumab | United States | Marketed | 2010 |
| ACTEMRA162mg/0.9ml · Injectable | Tocilizumab | United States | Marketed | 2013 |
| ACTIVASE100mg/vial | 50mg/vial · Vial | Alteplase | United States | Marketed | 1987 |
| AVASTIN100mg | 400mg · Vial | Bevacizumab | United States | Marketed | 2004 |
| CATHFLO ACTIVASE2mg/vial · Vial | Alteplase | United States | Marketed | 1987 |
| COLUMVI10mg/10ml(1mg/ml) | 2.5mg/2.5ml(1mg/ml) · Injectable | Glofitamab | United States | Marketed | 2023 |
| COTELLIC20mg base · Tablet | Cobimetinib | United States | Marketed | 2015 |
| ENSPRYNG120mg/ml · Injectable | Satralizumab | United States | Marketed | 2020 |
| ERIVEDGE150mg · Capsule | Vismodegib | United States | Marketed | 2012 |
| EVRYSDI5MG · Tablet | Risdiplam | United States | Marketed | 2025 |
| EVRYSDI0.75mg/ml · For solution | Risdiplam | United States | Marketed | 2020 |
| GAZYVA1000mg/40ml · Injectable | Obinutuzumab | United States | Marketed | 2013 |
| Hemlibra300mg/2ml (150mg/ml) · Injection | Emicizumab | United States | Marketed | 2023 |
| HEMLIBRA105mg/0.7ml | 150mg | 30mg/ml | 60mg/0.4ml · Injectable | Emicizumab | United States | Marketed | 2017 |
| Hemlibra12mg/0.4ml · Injection | Emicizumab | United States | Marketed | 2024 |
| HERCEPTIN21mg/ml · Vial | Trastuzumab | United States | Marketed | 1998 |
| Herceptin150mg · For Injection | Trastuzumab | United States | Marketed | 2017 |
| HERCEPTIN HYLECTA600mg · Injectable | Trastuzumab, Hyaluronidase | United States | Marketed | 2019 |
| ITOVEBI3mg | 9mg · Tablet | Inavolisib | United States | Marketed | 2024 |
| KADCYLA100mg | 160mg · Vial | Ado-trastuzumab emtansine | United States | Marketed | 2013 |
| LUCENTIS10mg/ml | 6mg/ml · Injectable | Ranibizumab | United States | Marketed | 2006 |
| Lucentis6mg/ml (0.3mg/0.05ml) · Injection | Ranibizumab | United States | Marketed | 2018 |
| Lucentis10mg/ml (0.5mg/0.05ml) · Injection | Ranibizumab | United States | Marketed | 2016 |
| LUNSUMIO1mg/ml | 30mg/30ml · Injectable | Mosunetuzumab | United States | Marketed | 2022 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 59 | 58 | 1 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.